期刊文献+

过表达中期因子增强SMMC 7721细胞对5-Fu耐药及可能机制研究

Overexpression of midkine enhancing resistance of SMMC 7721 cells to 5-Fu and its possible mechanism
下载PDF
导出
摘要 目的探讨过表达中期因子(MK)增强SMMC 7721细胞对5-氟尿嘧啶(5-Fu)耐药及其可能的机制。方法将SMMC 7721细胞转染pIRES2-EGFP-MK重组质粒过表达,采用实时荧光定量PCR(qPCR)和蛋白质印迹法(WB)检测MK mRNA和蛋白的表达。5-Fu处理后,采用MTT法检测SMMC 7721细胞对5-Fu的耐药。采用WB法检测磷酸化磷脂酰肌醇3-激酶(p-PI3K)、磷酸化蛋白激酶B(p-Akt)和NF-κB及Bcl-2、survivin、caspase-3的表达。结果将SMMC 7721细胞转染pIRES2-EGFP-MK重组质粒过表达后,MK mRNA和蛋白的表达增加,ConC组细胞对5-Fu的IC50显著高于Con-A组、Con-B组[(27.36±4.31)mg/L vs (4.57±0.34)mg/L,(4.96±0.46)mg/L],差异具有统计学意义(P<0.05)。此外,与Con-A组、Con-B组比较,Con-C组细胞p-PI3K(0.66±0.04 vs 0.35±0.03,0.57±0.03)、p-Akt (0.31±0.02 vs 0.17±0.02、0.25±0.02)、NF-κB (0.63±0.05 vs 0.27±0.02,0.53±0.04)、Bcl-2(0.42±0.04 vs 0.13±0.01, 0.38±0.04)、survivin(0.58±0.04 vs 0.18±0.02,0.51±0.04)呈现高表达,caspase-3(0.41±0.04vs 0.88±0.06,0.43±0.03)呈现低表达(P<0.05)。结论过表达MK可增强SMMC 7721细胞对5-Fu耐药,其机制可能与激活PI3K/AKT信号通路有关。 Objective To investigate the effect of overexpression of midkine(MK) on the resistance of SMMC 7721 cells to 5-fluorouracil(5-Fu) and its possible mechanism. Methods SMMC 7721 cells were transfected into pIRES2-EGFPMK recombinant plasmid for overexpression. Real-time quantitative PCR(qPCR) and Western blot(WB) were used to detect the expression of MK mRNA and protein. After 5-Fu treatment, the resistance of SMMC 7721 cells to 5-Fu was detected by MTT assay. The expression of phosphorylated phosphatidylinositol 3-kinase(p-PI3 K), phosphorylated protein kinase B(p-Akt) and NF-κB, and Bcl-2, survivin and caspase-3 were detected by WB assay. Results After overexpression of SMMC 7721 cells transfected with pIRES2-EGFP-MK recombinant plasmid, the expression of MK mRNA and protein increased, and the IC50 of 5-Fu in Con-C group increased significantly than that in the Con-A group and Con-B group[(27.36±4.31) mg/L vs 4.57±0.34] mg/L,(4.96±0.46) mg/L], and the difference was statistically significant(P<0.05).In addition, compared with the Con-A group and Con-B group, p-PI3 K(0.66±0.04 vs 0.35±0.03, 0.57±0.03), p-Akt(0.31±0.02 vs 0.17±0.02, 0.25±0.02), NF-κB(0.63±0.05 vs 0.27±0.02, 0.53±0.04), Bcl-2(0.42±0.04 vs 0.13±0.01,0.38±0.04), survivin(0.58±0.04 vs 0.18±0.02, 0.51±0.04) showed high expression, caspase-3(0.41±0.04 vs 0.88±0.06,0.43±0.03) showed low expression in the Con-C group(P<0.05). Conclusion Overexpression of MK can enhance the resistance of SMMC 7721 cells to 5-Fu, and its mechanism may be related to the activation of PI3 K/AKT signaling pathway.
作者 慎华平 徐杰伟 朱霄峰 邱建 魏云海 张国雷 黄惠莲 严强 SHEN Huaping;XU Jiewei;ZHU Xiaofeng;QIU Jian;WEI Yunhai;ZHANG Guolei;HUANG Huilian;YAN Qiang(Department of General Surgery, Huzhou Central Hospital in Zhejiang Province, Huzhou 313000, China;Department of Obstetrics and Gynecology, Huzhou Central Hospital in Zhejiang Province, Huzhou 313000, China;Center for Precision Medicine Clinical Research, Huzhou Central Hospital in Zhejiang Province, Huzhzou 313000, China)
出处 《中国现代医生》 2019年第18期41-45,共5页 China Modern Doctor
基金 浙江省自然科学基金一般项目(LY17H160004) 浙江省湖州市公益性技术应用研究项目(2014GY07)
关键词 肝癌 SMMC 7721细胞 中期因子 5-氟尿嘧啶 磷脂酰肌醇3-激酶 蛋白激酶B Liver cancer SMMC 7721 cells Midkine 5-fluorouracil Phosphatidylinositol 3-kinase Protein kinase B
  • 相关文献

参考文献4

二级参考文献100

  • 1Finn RS. Development of molecularly targeted therapies inhepatocellular carcinoma: where do we go now- Clin Cancer Res2010; 16: 390-397 [PMID: 20068087 DOI: 10.1158/1078-0432.CCR-09-2084].
  • 2Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma.Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0].
  • 3Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, MoFK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT,Tang A, Johnson PJ. A randomized phase III study of doxorubicinversus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil(PIAF) combination chemotherapy for unresectable hepatocellularcarcinoma. J Natl Cancer Inst 2005; 97: 1532-1538 [PMID:16234567 DOI: 10.1093/jnci/dji315].
  • 4Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS,Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ. Completepathological remission is possible with systemic combinationchemotherapy for inoperable hepatocellular carcinoma. ClinCancer Res 1999; 5: 1676-1681 [PMID: 10430068].
  • 5Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L,Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, BonnetainF, Boige V, Tab J. Gemcitabine plus oxaliplatin in advancedhepatocellular carcinoma: a large multicenter AGEO study. J Hepatol2013; 58: 81-88 [PMID: 22989572 DOI: 10.1016/j.jhep.2012.09.006].
  • 6Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS,Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized,multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy inpatients with advanced hepatocellular carcinoma from Asia. J ClinOncol 2013; 31: 3501-3508 [PMID: 23980077 DOI: 10.1200/JCO.2012.44.5643].
  • 7Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I,Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenibvs doxorubicin alone in patients with advanced hepatocellularcarcinoma: a randomized trial. JAMA 2010; 304: 2154-2160 [PMID:21081728 DOI: 10.1001/jama.2010.1672].
  • 8Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, SoulenMC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, ShakedA, Reddy R, Olthoff K. Phase 2 trial of bevacizumab, capecitabine,and oxaliplatin in treatment of advanced hepatocellular carcinoma.Cancer 2011; 117: 3187-3192 [PMID: 21264839 DOI: 10.1002/cncr.25889].
  • 9Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, RongH, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J,Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M,Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, PostLE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrumoral antitumor activity and targets the RAF/MEK/ERK pathwayand receptor tyrosine kinases involved in tumor progression andangiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206DOI: 10.1158/0008-5472.CAN-04-1443].
  • 10Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, PortaC, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, BorbathI, H-ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,Bruix J. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857].

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部